Cardiovascular disease (CVD) remains a leading cause of mortality worldwide, with lipoprotein(a) [Lp(a)] emerging as a critical risk factor. Despite its significance, Lp(a) is not routinely measured in clinical practice, making it difficult to identify and recruit eligible patients for atherosclerotic cardiovascular disease (